Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BB Biotech ( (CH:BION) ) just unveiled an announcement.
BB Biotech AG reported a sharp turnaround in 2025 with a preliminary net profit of CHF 578 million versus CHF 76 million a year earlier, driven by a strong share price total return of up to 53.7% in USD terms and net asset value gains that outpaced the Nasdaq Biotechnology Index for both the full year and the fourth quarter. The company’s share discount to NAV narrowed to 10.8% at year-end amid improving investor sentiment, and the board will ask shareholders to approve a higher ordinary dividend of CHF 2.25 per share for 2026, implying a 5% yield and underscoring its intention to balance robust shareholder payouts with continued reinvestment in long-term biotech growth opportunities.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF56.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is a listed Swiss investment company based in Schaffhausen that specializes in investing in innovative drug development firms, primarily in the United States and Western Europe. Active since 1993 and traded on the Swiss, Frankfurt (Prime Standard) and Milan exchanges, it is considered one of the leading investors in the biotechnology sector, with its board setting strategy and Bellevue Asset Management’s investment team executing research-driven portfolio decisions.
Average Trading Volume: 86,468
Technical Sentiment Signal: Buy
Current Market Cap: CHF2.58B
For an in-depth examination of BION stock, go to TipRanks’ Overview page.